000829380 001__ 829380
000829380 005__ 20240625095127.0
000829380 0247_ $$2doi$$a10.1007/s00262-015-1763-8
000829380 0247_ $$2ISSN$$a0340-7004
000829380 0247_ $$2ISSN$$a1432-0851
000829380 0247_ $$2WOS$$aWOS:000365176600008
000829380 0247_ $$2altmetric$$aaltmetric:4633258
000829380 0247_ $$2pmid$$apmid:26472728
000829380 037__ $$aFZJ-2017-03093
000829380 082__ $$a610
000829380 1001_ $$0P:(DE-HGF)0$$aCremer, Christian$$b0
000829380 245__ $$aNovel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo
000829380 260__ $$aBerlin$$bSpringer$$c2015
000829380 3367_ $$2DRIVER$$aarticle
000829380 3367_ $$2DataCite$$aOutput Types/Journal article
000829380 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1493015841_17726
000829380 3367_ $$2BibTeX$$aARTICLE
000829380 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000829380 3367_ $$00$$2EndNote$$aJournal Article
000829380 520__ $$aImmunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ligand with a cytotoxic effector component that induces apoptosis in specific cell populations displaying the corresponding antigen or receptor. Human cytolytic fusion proteins (hCFPs) are less immunogenic than conventional immunotoxins because they contain human pro-apoptotic enzymes as effectors. However, one drawback of hCFPs is that target cells can protect themselves by expressing endogenous inhibitor proteins. Inhibitor-resistant enzyme mutants that maintain their cytotoxic activity are therefore promising effector domain candidates. We recently developed potent variants of the human ribonuclease angiogenin (Ang) that were either more active than the wild-type enzyme or less susceptible to inhibition because of their lower affinity for the ribonuclease inhibitor RNH1. However, combining the mutations was unsuccessful because although the enzyme retained its higher activity, its susceptibility to RNH1 reverted to wild-type levels. We therefore used molecular dynamic simulations to determine, at the atomic level, why the affinity for RNH1 reverted, and we developed strategies based on the introduction of further mutations to once again reduce the affinity of Ang for RNH1 while retaining its enhanced activity. We were able to generate a novel Ang variant with remarkable in vitro cytotoxicity against HL-60 cells and pro-inflammatory macrophages. We also demonstrated the pro-apoptotic potential of Ang-based hCFPs on cells freshly isolated from leukemia patients.
000829380 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000829380 588__ $$aDataset connected to CrossRef
000829380 7001_ $$0P:(DE-HGF)0$$aBraun, Hanna$$b1
000829380 7001_ $$0P:(DE-HGF)0$$aMladenov, Radoslav$$b2
000829380 7001_ $$0P:(DE-HGF)0$$aSchenke, Lea$$b3
000829380 7001_ $$0P:(DE-HGF)0$$aCong, Xiaojing$$b4
000829380 7001_ $$0P:(DE-HGF)0$$aJost, Edgar$$b5
000829380 7001_ $$0P:(DE-HGF)0$$aBrümmendorf, Tim H.$$b6
000829380 7001_ $$0P:(DE-HGF)0$$aFischer, Rainer$$b7
000829380 7001_ $$0P:(DE-Juel1)145614$$aCarloni, Paolo$$b8$$ufzj
000829380 7001_ $$0P:(DE-HGF)0$$aBarth, Stefan$$b9
000829380 7001_ $$0P:(DE-HGF)0$$aNachreiner, Thomas$$b10$$eCorresponding author
000829380 773__ $$0PERI:(DE-600)1458489-x$$a10.1007/s00262-015-1763-8$$gVol. 64, no. 12, p. 1575 - 1586$$n12$$p1575 - 1586$$tCancer immunology immunotherapy$$v64$$x1432-0851$$y2015
000829380 8564_ $$uhttps://juser.fz-juelich.de/record/829380/files/art_10.1007_s00262-015-1763-8.pdf$$yRestricted
000829380 8564_ $$uhttps://juser.fz-juelich.de/record/829380/files/art_10.1007_s00262-015-1763-8.gif?subformat=icon$$xicon$$yRestricted
000829380 8564_ $$uhttps://juser.fz-juelich.de/record/829380/files/art_10.1007_s00262-015-1763-8.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000829380 8564_ $$uhttps://juser.fz-juelich.de/record/829380/files/art_10.1007_s00262-015-1763-8.jpg?subformat=icon-180$$xicon-180$$yRestricted
000829380 8564_ $$uhttps://juser.fz-juelich.de/record/829380/files/art_10.1007_s00262-015-1763-8.jpg?subformat=icon-640$$xicon-640$$yRestricted
000829380 8564_ $$uhttps://juser.fz-juelich.de/record/829380/files/art_10.1007_s00262-015-1763-8.pdf?subformat=pdfa$$xpdfa$$yRestricted
000829380 909CO $$ooai:juser.fz-juelich.de:829380$$pVDB
000829380 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145614$$aForschungszentrum Jülich$$b8$$kFZJ
000829380 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000829380 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000829380 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000829380 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000829380 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000829380 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER IMMUNOL IMMUN : 2015
000829380 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000829380 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000829380 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000829380 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000829380 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000829380 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000829380 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000829380 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000829380 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000829380 920__ $$lyes
000829380 9201_ $$0I:(DE-Juel1)GRS-20100316$$kGRS Jülich ; German Research School for Simulation Sciences$$lGRS$$x0
000829380 9201_ $$0I:(DE-Juel1)IAS-5-20120330$$kIAS-5$$lComputational Biomedicine$$x1
000829380 980__ $$ajournal
000829380 980__ $$aVDB
000829380 980__ $$aI:(DE-Juel1)GRS-20100316
000829380 980__ $$aI:(DE-Juel1)IAS-5-20120330
000829380 980__ $$aUNRESTRICTED
000829380 981__ $$aI:(DE-Juel1)INM-9-20140121